Skip to search formSkip to main contentSkip to account menu

STX 140

Known as: STX-140, STX140 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
3,17 beta-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and Nonsteroidal Sulfamate Derivatives Inhibit Carbonic Anhydrase IX: Structure-Activity Optimization for Isoform Selectivity.
3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene (STX140), a bis-sulfamate derivative of the endogenous steroid 2… 
2012
2012
Abstract 2795: Safety profile and therapeutic potential in breast cancer of STX140, an original tubulin binding agent
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL STX-140 is an anti-tubulin binding agent which has… 
2011
2011
The effects of paclitaxel and STX140 on early-and late-stage breast cancer in tte clinically relevant C3(1)/SV40 mouse model
2010
2010
Abstract 1558: STX140 but not paclitaxel inhibits mammary tumor initiation, progression and metastasis in C3(1)/SV40 T/t-antigen transgenic mice
New chemotherapeutic options for late-stage metastatic breast cancer are urgently required. Currently, the taxanes are considered… 
2010
2010
Abstract 4413: STX140 is an orally bioavailable microtubule targeting agent with no associated peripheral neuropathy and potent anti-metastasis efficacy in vivo
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC There is a continued need for orally bioavailable… 
Highly Cited
2008
Highly Cited
2008
STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells
Purpose: The aim of these studies was to characterize the action of STX140 in a P-glycoprotein–overexpressing tumor cell line… 
2008
2008
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer.
UNLABELLED There is a continued need for orally bioavailable anticancer compounds that exhibit good efficacy against breast… 
2008
2008
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.
UNLABELLED This study characterises two recently developed anticancer agents in vitro and in vivo, 2-methoxyoestra-1,3,5(10), 16… 
2007
2007
The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers
Therapies for hormone-independent prostate and breast cancer are limited, with the effectiveness of the taxanes compromised by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)